These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 22248877)

  • 1. Genetic mutations in chronic myelogenous leukemia: when to check and what to do?
    Berman E
    Curr Opin Hematol; 2012 Mar; 19(2):110-6. PubMed ID: 22248877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. Single center experience].
    Sacha T; Foryciarz K; Florek I; Zawada M; Czekalska S; Cwynar D; Pecek E; Skotnicki AB
    Przegl Lek; 2011; 68(5):253-7. PubMed ID: 21961412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to imatinib: mutations and beyond.
    La Rosée P; Deininger MW
    Semin Hematol; 2010 Oct; 47(4):335-43. PubMed ID: 20875550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Implementation of direct sequencing as a method of ABL gene mutations analysis in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor].
    Florek I; Sacha T; Zawada M; Czekalska S; Foryciarz K; Cwynar D; Pecek E; Skotnicki AB
    Przegl Lek; 2010; 67(12):1292-7. PubMed ID: 21591355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
    Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K; Janssens A; Verhoef G; Vandenberghe P
    Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
    Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
    Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
    Yamamoto K; Yakushijin K; Nishikawa S; Minagawa K; Katayama Y; Shimoyama M; Matsui T
    Cancer Genet Cytogenet; 2008 May; 183(1):77-81. PubMed ID: 18474303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring treatment of chronic myeloid leukemia.
    Baccarani M; Pane F; Saglio G
    Haematologica; 2008 Feb; 93(2):161-9. PubMed ID: 18245647
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
    La Rosée P; Corbin AS; Stoffregen EP; Deininger MW; Druker BJ
    Cancer Res; 2002 Dec; 62(24):7149-53. PubMed ID: 12499247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.